Copyright
©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 21, 2007; 13(39): 5188-5195
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5188
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5188
Figure 2 A: Clinical course of the interferon group.
Patients who had a curative treatment for primary HCC received 3 MIU of natural interferon-alpha three times weekly for at least 48 wk as long as possible except Cases 12, 14 and 16. Recurrent HCCs were treated with or without curative treatment; B: Clinical course of the non-interferon group. Patients who had a curative treatment of primary HCC did not receive IFN therapy. Recurrent HCCs were also treated with or without curative treatment.
- Citation: Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13(39): 5188-5195
- URL: https://www.wjgnet.com/1007-9327/full/v13/i39/5188.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i39.5188